Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer

Detalles Bibliográficos
Autores principales: O’Shea, Anne E., Clifton, Guy T., Peoples, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590818/
https://www.ncbi.nlm.nih.gov/pubmed/34786184
http://dx.doi.org/10.18632/oncotarget.27998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590818/
https://www.ncbi.nlm.nih.gov/pubmed/34786184
http://dx.doi.org/10.18632/oncotarget.27998

Ejemplares similares